ADC Payload & Linker Patents

Antibody-drug conjugate (ADC) patents cover cytotoxic-payload innovations; linker-chemistry innovations; conjugation and drug-antibody-ratio (DAR) innovations; and bystander-effect and next-generation-modality innovations — with IP held by the platform pioneers whose payload-linker technology powers most marketed ADCs (the antibody targets the cancer; the payload-linker is the 'warhead' and the technical core). MAJOR ADC PAYLOAD/LINKER PATENT HOLDERS: DAIICHI SANKYO (AstraZeneca): the DXd platform — Enhertu (trastuzumab deruxtecan) uses DXd (an exatecan-derivative topoisomerase-I inhibitor) on a cleavable tetrapeptide linker at high drug-antibody ratio (DAR ~8) with a strong bystander effect — a breakthrough that redefined ADCs; also datopotamab deruxtecan (Dato-DXd). SEAGEN (Pfizer): the vedotin platform — Adcetris (brentuximab vedotin) and Padcev use MMAE (monomethyl auristatin E, a microtubule inhibitor) with a cleavable valine-citrulline (vc) protease-sensitive linker; foundational auristatin/vc-linker IP. IMMUNOGEN (AbbVie): maytansinoid payloads (DM1, DM4) and linkers — Kadcyla (T-DM1) and Elahere (mirvetuximab soravtansine). OTHERS: Pfizer/Wyeth (calicheamicin — Mylotarg, Besponsa), Ambrx and Sutro Biopharma (site-specific conjugation via engineered cysteines/unnatural amino acids/cell-free synthesis), Mersana (Dolaflexin/polymer scaffold), Bicycle Therapeutics (bicyclic-peptide-toxin conjugates), and Synaffix and others. Payload class, linker chemistry, and conjugation/DAR are the core ADC patent domains — and these platform technologies are licensed across the industry.

Payload-class and potency innovations; topoisomerase and novel-payload innovations; cleavable and non-cleavable linker innovations; and stability and release innovations represent core ADC patent domains — and the payload (a highly potent cytotoxin too toxic to give systemically) plus the linker (controlling where/when it releases) are the technical heart of an ADC. PAYLOAD PATENTS: cytotoxic payload classes — auristatins (MMAE/MMAF, microtubule inhibitors — Seagen), maytansinoids (DM1/DM4, microtubule inhibitors — ImmunoGen), TOPOISOMERASE-I inhibitors (DXd/deruxtecan, SN-38, exatecan derivatives — the Daiichi-driven shift to moderately-potent, high-DAR topoisomerase payloads that gave Enhertu its profile), pyrrolobenzodiazepine PBD dimers and other DNA-damaging agents, calicheamicin, and emerging payloads (immune agonists like STING/TLR for immune-stimulating ADCs, and degrader/PROTAC payloads — DACs); the specific payload molecule and its potency/mechanism are key composition claims. LINKER PATENTS: cleavable linkers (protease-sensitive valine-citrulline, acid-labile hydrazone, glutathione-sensitive disulfide) that release the payload inside the tumor cell, and non-cleavable (thioether) linkers (releasing a payload-amino-acid adduct after antibody degradation); linker stability in circulation (preventing premature release/toxicity) and bystander-enabling membrane-permeable released payloads. STABILITY / RELEASE PATENTS: serum stability, controlled intratumoral release, and reduced off-target toxicity. The payload class (especially novel/topoisomerase/immune/degrader payloads) and stable, tumor-selective-release linkers are the highest-value ADC IP.

Conjugation-chemistry innovations; site-specific-conjugation innovations; drug-antibody-ratio control innovations; and bystander-effect and homogeneity innovations represent additional ADC patent domains — and HOW the payload-linker is attached to the antibody determines homogeneity, stability, and therapeutic window. CONJUGATION PATENTS: conventional conjugation to native antibody lysines (random, heterogeneous mixture) or to interchain-disulfide cysteines (Seagen/ImmunoGen approaches), and the chemistry of attachment. SITE-SPECIFIC CONJUGATION PATENTS: attaching payloads at defined, engineered sites for a HOMOGENEOUS, defined-DAR product — engineered cysteines (THIOMAB), unnatural/non-canonical amino acids (Ambrx), enzymatic conjugation (transglutaminase, sortase, GlycoConnect — Synaffix), and cell-free site-specific synthesis (Sutro) — site-specific conjugation improves homogeneity, stability, and therapeutic index and is a high-value, distinct platform IP. DAR-CONTROL PATENTS: controlling the drug-antibody ratio (the average number of payloads per antibody — too low loses potency, too high causes aggregation/fast clearance; Daiichi achieved a stable high DAR ~8) and DAR distribution/homogeneity. BYSTANDER-EFFECT PATENTS: designing the released payload to be membrane-permeable so it can kill neighboring antigen-low tumor cells (the bystander effect that broadened Enhertu to HER2-low tumors) — a key efficacy lever. HOMOGENEITY / ANALYTICS PATENTS: manufacturing and characterization of a defined ADC. Site-specific conjugation, stable high-DAR designs, and tunable bystander effect are the highest-value ADC platform IP because they set the therapeutic window.

ADC startup IP strategy must navigate Seagen vedotin/auristatin/vc-linker patents, Daiichi DXd/topoisomerase patents, ImmunoGen maytansinoid patents, the deep, licensed-across-industry payload-linker platform estates, the underlying antibody IP (see antibody therapeutics), and a landscape where the payload-linker-conjugation platform — not the antibody alone — is the technical core and the most-licensed IP; understand that the marketed payload-linker platforms (vedotin, DXd, maytansinoid) are heavily patented and widely licensed (you often license a platform OR build a differentiated one), that the durable startup IP is in a novel payload, a novel linker, site-specific conjugation, or a new modality (immune-stimulating or degrader payloads), and that the ADC molecule's value still depends on the antibody/target; identify whitespace in novel payloads, site-specific conjugation, new linker chemistries, and ADC-beyond-cytotoxin modalities. ADC STARTUP IP STRATEGY: THE PAYLOAD-LINKER-CONJUGATION PLATFORM IS THE TECHNICAL CORE — LICENSE OR DIFFERENTIATE: the marketed platforms (Seagen vedotin, Daiichi DXd, ImmunoGen maytansinoid) are densely patented and widely licensed — either license a platform or build a genuinely differentiated payload/linker/conjugation to own your IP; NOVEL PAYLOADS AND NEW MODALITIES ARE HIGHEST-VALUE WHITESPACE: beyond microtubule/topoisomerase cytotoxins, immune-stimulating ADCs (STING/TLR agonists), degrader-antibody conjugates (DACs — PROTAC payloads), and novel-mechanism payloads are the open frontier; SITE-SPECIFIC CONJUGATION IS A DISTINCT, VALUABLE PLATFORM: homogeneous, defined-DAR ADCs via engineered cysteines/unnatural amino acids/enzymatic conjugation (Ambrx/Sutro/Synaffix) improve therapeutic index and are patentable platform IP; LINKER AND BYSTANDER TUNING SET THE THERAPEUTIC WINDOW: stable, tumor-selective-release linkers and tunable bystander effect (Enhertu's lever) are high-value, patentable design IP; THE ANTIBODY/TARGET STILL MATTERS: an ADC's value depends on the antibody and target too — see antibody therapeutics for that FTO; WHEN TO PATENT: NOVEL PAYLOAD/LINKER/CONJUGATE WITH MEASURED PERFORMANCE: file once an ADC component shows measured results (payload potency + linker stability/release + DAR/homogeneity + bystander + therapeutic index + efficacy) — measured payload potency, linker stability, DAR homogeneity, and therapeutic index are the critical ADC IP metrics; KEY FTO CHECKLIST: Seagen vedotin MMAE/MMAF auristatin + valine-citrulline cleavable linker; Daiichi DXd deruxtecan exatecan topoisomerase-I + tetrapeptide linker high-DAR bystander (Enhertu); ImmunoGen DM1/DM4 maytansinoid + SMCC/SPDB linker; Pfizer calicheamicin; PBD dimer; immune-agonist (STING/TLR) and degrader (DAC) payloads; cleavable (vc/hydrazone/disulfide) vs non-cleavable thioether linker; site-specific conjugation (THIOMAB cysteine / Ambrx unnatural-amino-acid / Synaffix enzymatic / Sutro cell-free); DAR control/homogeneity; bystander membrane-permeable payload; antibody/target FTO.